In 2019, we reported potent small molecule inhibitors that bind the WIN site of WDR5 with picomolar affinity, specifically block the HMT activity of MLL1 complexes, and selectively kill MLLr leukemia cells in culture—recapitulating much of the behavior of MM-104 [16]. Here, WDR5 is linked to leukemia.